Unique Wealth LLC Buys 1,054 Shares of Eli Lilly and Company (NYSE:LLY)

Unique Wealth LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 303.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,401 shares of the company’s stock after acquiring an additional 1,054 shares during the period. Unique Wealth LLC’s holdings in Eli Lilly and Company were worth $1,241,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at about $262,000. CHURCHILL MANAGEMENT Corp acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. HighPoint Advisor Group LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $3,355,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LLY. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Barclays upped their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research note on Thursday. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Finally, Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Trading Down 0.7 %

LLY opened at $885.15 on Friday. The company has a fifty day moving average price of $898.50 and a two-hundred day moving average price of $846.49. Eli Lilly and Company has a 1-year low of $523.63 and a 1-year high of $972.53. The company has a market cap of $841.25 billion, a P/E ratio of 130.36, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.